en · de · es · fr · pt
cardarine-notes.peptides3626.com › Wiki › Identity And Regulatory Status — Field Notes

Identity And Regulatory Status — Field Notes

By Editorial Desk · published 2025-08-15 · last reviewed 2025-09-14 · Wiki

Everything below concerns WADA Prohibited List. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Updated 2025-09-14. Numbers and descriptions here follow the published literature rather than marketing material.

Identity and Regulatory Status

Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.

Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.

Regulatory Status and Detection Context

Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.

A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.

Cardarine at a glance

PropertyValueNotes
Common synonymsGW501516; GW-1516; endurobolGW501516 is the research code
Drug classPPARδ agonistNot a selective androgen receptor modulator
Molecular formulaC21H18F3NO3S2Established chemical formula
Molar mass453.5 g/molCalculated from the formula
Regulatory statusProhibited in sport; not approved as medicineStatus varies by country

Detection, Regulation, and Quality Context

Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.

Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.

Related pages on this site

Detection, Stability, and Quality

Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.

Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.

Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.

Preclinical Findings and Safety Signals

Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.

Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.

Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.

Supporting material

In 1738, Swiss physicist and mathematician Daniel Bernoulli postulated that the pressure of gases and heat were both caused by the underlying motion of molecules. Using his model he could predict the ideal gas law at constant temperature and suggested that the temperature was proportional to the velocity of the particles. This success was not followed up, in part because the then new tools of calculus allowed more progress using continuous models for gases. James Clerk Maxwell, a vocal proponent of atomism, revived the kinetic theory in 1860 and 1867. His key insight was that the velocity of particles in a gas would vary around an average value, introducing the concept of a distribution function. In the late 1800s, Ludwig Boltzmann used atomic models to apply kinetic theory to thermodynamics especially the second law relating to entropy. Boltzmann defended the atomistic hypothesis against major detractors from the time like Ernst Mach or energeticists like Wilhelm Ostwald, who considered that energy was the elementary quantity of reality. However an atomic model was not essential for the development of theory of thermodynamics. This became clear when Josiah Willard Gibbs introduced statistical mechanics in his 1902 book Elementary Principles in Statistical Mechanics. His logical and formal development of a new approach specifically avoided requiring an atomic hypothesis. Albert Einstein independently developed an approach similar to Gibbs, but with a completely different aim: Einstein set out to find a way to verify the atomic hypothesis through the kinetic theory.

=== Film and television === AAA, la película: sin límite en el tiempo, a 2010 Mexican movie Anbanavan Asaradhavan Adangadhavan, a 2017 Indian Tamil-language movie Associated Argentine Artists (Spanish: Artistas Argentinos Asociados), an Argentine movie distribution company Spearhead from Space, a 1970 Doctor Who serial (production code "AAA")

=== Modern accounts === Goldstein, Martin, and Inge F., (1993). The Refrigerator and the Universe. Harvard Univ. Press. A gentle introduction. Kroemer, Herbert; Kittel, Charles (1980). Thermal Physics (2nd ed.). W. H. Freeman Company. ISBN 978-0-7167-1088-2. Nolan, Peter J. (1996). Fundamentals of College Physics, 2nd ed. William C. Brown Publishers. Oxtoby & Nachtrieb (1996). Principles of Modern Chemistry, 3rd ed. Saunders College Publishing. Papineau, D. (2002). Thinking about Consciousness. Oxford: Oxford University Press. Serway, Raymond A.; Jewett, John W. (2004). Physics for Scientists and Engineers (6th ed.). Brooks/Cole. ISBN 978-0-534-40842-8. Stenger, Victor J. (2000). Timeless Reality. Prometheus Books. Especially chpt. 12. Nontechnical. Tipler, Paul (2004). Physics for Scientists and Engineers: Mechanics, Oscillations and Waves, Thermodynamics (5th ed.). W. H. Freeman. ISBN 978-0-7167-0809-4. Lanczos, Cornelius (1970). The Variational Principles of Mechanics. Toronto: University of Toronto Press. ISBN 978-0-8020-1743-7.

== Metabolism == As of 2006, five biosynthesis pathways had been reported for trehalose. The most common pathway is TPS/TPP pathway which is used by organisms that synthesize trehalose using the enzyme trehalose-6-phosphate (T6P) synthase (TPS). As of 2006, this was the only known synthetic pathway in fungi, plants and invertebrates. Second, trehalose synthase (TS) in certain types of bacteria could produce trehalose by using maltose and another disaccharide with two glucose units as substrates. Third, the TreY-TreZ pathway in some bacteria converts starch that contain maltooligosaccharide or glycogen directly into trehalose. Fourth, in primitive bacteria, trehalose glycisyltransferring synthase (TreT) produces trehalose from ADP-glucose and glucose. Fifth, trehalose phosphorylase (TreP) either hydrolyses trehalose into glucose-1-phosphate and glucose or may act reversibly in certain species. Vertebrates do not have the ability to synthesize or store trehalose. Trehalase, an enzyme which metabolizes trehalose, is found in humans only in specific locations such as the intestinal mucosa, renal brush-border, liver and blood. Expression of this enzyme in vertebrates is initially found during the gestation period that is the highest after weaning. Afterwards the level of trehalase remains constant in the intestine throughout life. Diets consisting of plants and fungi contain trehalose.

Sources: en.wikipedia.org

Supporting material

=== AFL policy === The AFL is a signatory to ASADA and WADA, and its policy on performance-enhancing drugs is based upon those organisations. For non-performance-enhancing drugs, the AFL currently has a "three-strikes" policy, under which only the player and the club doctor are aware of any positive tests until a third such test is received. After the third strike, the club is made aware of the situation and the player may face disciplinary action. This policy has faced criticism for leniency from anti-doping bodies, particularly the World Anti-Doping Agency (WADA), and as such has attracted much media scrutiny and public debate.

== Clinical comparisons of effectiveness == A 2006 review article in the journal "Lasers in Medical Science" compared intense pulsed light (IPL) and both alexandrite and diode lasers. The review found no statistical difference in effectiveness, but a higher incidence of side effects with diode laser-based treatment. Hair reduction after 6 months was reported as 68.75% for alexandrite lasers, 71.71% for diode lasers, and 66.96% for IPL. Side effects were reported as 9.5% for alexandrite lasers, 28.9% for diode lasers, and 15.3% for IPL. All side effects were found to be temporary and even pigmentation changes returned to normal within 6 months. A 2006 meta-analysis of randomized controlled trials found that alexandrite and diode lasers caused 50% hair reduction for up to 6 months, while there was no evidence of hair reduction from intense pulsed light, neodymium-YAG or ruby lasers.

The longest non-compound (a single stem with prefixes and suffixes) Finnish word recognised by the Guinness Book of Records is epäjärjestelmällistyttämättömyydellänsäkäänköhänkään (see also Agglutination#Extremes), based on the stem järki (reason, sanity), and it means: "I wonder if – even with his/her quality of not having been made unsystematized". Äteritsiputeritsipuolilautatsijänkä and a defunct bar named after it, Äteritsiputeritsipuolilautatsi-baari, are the longest place names in use.

Sources: en.wikipedia.org

Notes from published material

Federal Prime Minister Milan Panić became frustrated with Milošević's domineering behaviour during diplomatic talks in 1992 and told Milošević to "shut up" because Milošević's position was officially subordinate to his position. Milošević later forced Panić to resign. This situation changed after 1997 when Milošević's second and last legal term as Serbian President ended. He then had himself elected Federal President, thus entrenching the power that he already de facto held. After the Federal Republic was reconstituted as a State Union, the new Assembly of the State Union was created. It was unicameral and was made up of 126 deputies, of which 91 were from Serbia and 35 were from Montenegro. The Assembly convened in the building of the old Federal Assembly of Yugoslavia, which now houses the National Assembly of Serbia. A direct, nationwide election was planned for 2005, but was subsequently delayed to 2006 in Montenegro and 2007 in Serbia to coincide with local parliamentary elections. Since the State Union dissolved before either was held, direct parliamentary elections were never held and the deputies were instead elected indirectly by the parliament of their respective republic. In 2003, after the constitutional changes and creation of the State Union of Serbia and Montenegro, a new President of Serbia and Montenegro was elected. He was also president of the Council of Ministers of Serbia and Montenegro. Svetozar Marović was the first and last President of Serbia and Montenegro until its breakup in 2006.

The coronary sinus is a large vein that drains into the right atrium, and receives most of the venous drainage of the heart. It receives blood from the great cardiac vein (receiving the left atrium and both ventricles), the posterior cardiac vein (draining the back of the left ventricle), the middle cardiac vein (draining the bottom of the left and right ventricles), and small cardiac veins. The anterior cardiac veins drain the front of the right ventricle and drain directly into the right atrium. Small lymphatic networks called plexuses exist beneath each of the three layers of the heart. These networks collect into a main left and a main right trunk, which travel up the groove between the ventricles that exists on the heart's surface, receiving smaller vessels as they travel up. These vessels then travel into the atrioventricular groove, and receive a third vessel which drains the section of the left ventricle sitting on the diaphragm. The left vessel joins with this third vessel, and travels along the pulmonary artery and left atrium, ending in the inferior tracheobronchial node. The right vessel travels along the right atrium and the part of the right ventricle sitting on the diaphragm. It usually then travels in front of the ascending aorta and then ends in a brachiocephalic node.

=== Among other animals === The hedgehog (Erinaceidae), the mongoose (Herpestidae), the honey badger (Mellivora capensis) and the opossum are known to be resistant to a dose of snake venom. Recently, the honey badger and domestic pig were found to have convergently evolved amino-acid replacements in their nicotinic acetylcholine receptor, which are known to confer resistance to alpha-neurotoxins in hedgehogs. Whether the pig may be considered immune is still uncertain, though early studies show endogenous resistance in pigs tested against neurotoxins. Though the pig's subcutaneous layer of fat may protect it against snake venom, most venoms pass easily through vascular fat layers, making this unlikely to contribute to its ability to resist venoms. The garden dormouse (Eliomys quercinus) has recently been added to the list of animals refractory to viper venom. Some populations of California ground squirrel (Otospermophilus beecheyi) are at least partially immune to rattlesnake venom as adults.

=== Consumption === Saffron's aroma is often described by connoisseurs as reminiscent of metallic honey with grassy or hay-like notes, while its taste has also been noted as hay-like and sweet. Consumed in large servings—more than a few threads per person per dish—saffron is experienced as bitter. Saffron also contributes a luminous yellow-orange colouring to foods. Saffron is widely used in Persian, Indian, European, and Arab cuisines. Confectioneries and liquors also often include saffron. Saffron is used in dishes ranging from the jewelled rice and khoresh of Iran, the Milanese risotto of Italy, the paella of Spain, the bouillabaisse of France, to the biryani with various meat accompaniments in South Asia. Saffron is also used in the preparation of the Golden Ham, a precious dry-cured ham made with saffron from San Gimignano in Tuscany. Common saffron substitutes include safflower (Carthamus tinctorius, which is often sold as "Portuguese saffron" or "açafrão"), annatto, and turmeric (Curcuma longa). In Medieval Europe, turmeric was also known as "Indian saffron" because of its yellow-orange colour.

Sources: en.wikipedia.org

Frequently asked questions

Is cardarine a SARM?

No. Cardarine is GW501516, a PPARδ agonist, while SARMs act on androgen receptors. The two classes are often grouped in informal discussions despite different mechanisms.

Is cardarine approved for human use?

No. It has no approved medical indication in any country. Regulatory agencies have not cleared it for treatment or prevention of any condition.

Why was its development discontinued?

Early clinical work stopped after rodent carcinogenicity findings. Those animal results raised concerns about long-term human risk, although direct human evidence is lacking. The human relevance of the tumors remains an open scientific question.

Is cardarine approved for any medical use?

No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.

Network